Neutrophils Engraftment Delay During Tigecycline Treatment in 2 Bone Marrow–transplanted Patients

• DOI: 10.1097/mph.0b013e318279eec2
• Publication Date: 2012-12-18T09:40:34Z
• Authors: Natalia Maximova; Davide Zanon; Federico Verzegnassi; Marilena Granzotto
• Keywords: Male; Neutropenia; Transplantation Conditioning; Adolescent; Neutrophils; Graft Survival; Minocycline; Prognosis; Combined Modality Therapy; Tigecycline; Transplantation, Autologous; Anti-Bacterial Agents; 3. Good health; Leukemia, Myeloid, Acute; Leukocyte Count; 03 medical and health sciences; 0302 clinical medicine; Humans; Female; Myeloid Cells; Child; Bone Marrow Transplantation

Tigecycline is the first available drug of glycylcycline family. Because of recent introduction, some of its adverse effects could be still unexplored.We report the cases of 2 boys who underwent an allogenic bone marrow transplantation for acute myeloid leukemia and were treated with tigecycline. Erythrocyte and platelet engraftment followed a normal course, but the neutrophil count remained low despite the increase in leukocyte count. After tigecycline interruption, the neutrophil count rapidly raised in both cases.Neutropenia was suspected to be secondary to tigecycline exposure. In vitro experiments were performed, which suggested tigecycline influence on myeloid cells survival.